Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill shows promise against tough breast and ovarian cancers

NCT ID NCT03519178

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug (PF-06873600) taken by mouth, alone or with hormone therapy, in people with advanced breast or ovarian cancers. The goal was to check safety and see if the drug could shrink tumors. The trial was stopped early, but results help guide future research.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

155 people

The number who actually took part.

Started

Mar 2018

Finished

Oct 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a diagnosis of Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) breast cancer • Prior combined CDK 4/6 inhibitor and endocrine therapy and 1 or 2 prior lines of chemotherapy * Have a diagnosis of metastatic triple negative breast cancer (TNBC) • Up to 1-2 prior lines of chemotherapy * Have a diagnosis of advanced platinum resistant epithelial ovarian cancer (EOC)/fallopian tube cancer/primary peritoneal cancer (PPC) • Up to 2-3 prior lines of therapy * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1 * Measurable disease or non-measurable disease and refractory to or intolerant of existing therapies (Part 1) * Measurable disease as defined by RECIST 1.1 is required (Part 1B and Part 2 only) Exclusion Criteria: * Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases * Other active malignancy within 3 years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ * Major surgery or radiation within 4 weeks prior to study entry * Last anti-cancer treatment within 2 weeks prior to study entry * Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry * Pregnant or breastfeeding female patients * Active inflammatory gastrointestinal (GI) disease, known diverticular disease or previous gastric resection or lap band surgery including impairment of gastro intestinal function or GI disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epithelial ovarian cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast neoplasm Carcinoma, Ovarian Epithelial fallopian tube cancer fallopian tube neoplasm hormone receptor-positive breast cancer male breast carcinoma ovarian cancer ovarian carcinoma primary peritoneal carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HR+ HER2- metastatic breast cancer, ovarian cancer, fallopian tube cancer, primary peritoneal cancer, triple negative breast cancer, male breast cancer

Contacts and locations

Locations

  • BIH of Omsk Region "Clinical Oncological Dispensary"

    Omsk, 644013, Russia

  • BIH of Omsk Region "Clinical Oncological Dispensary"

    Omsk, 644046, Russia

  • Brigham & Women's Hospital

    Boston, Massachusetts, 02115, United States

  • Communal noncommercial enterprise of Lviv regional council "Lviv oncological regional therapeutical

    Lviv, 79031, Ukraine

  • Communal nonprofit enterprise "Kyiv City Clinical Oncology Center" of Executive Body of Kyiv City

    Kyiv, 03115, Ukraine

  • Complex Oncology Center -Plovdiv

    Plovdiv, 4000, Bulgaria

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Fred Hutchinson Cancer Center

    Seattle, Washington, 98109, United States

  • Highlands Oncology

    Springdale, Arkansas, 72762, United States

  • Highlands Oncology Group

    Fayetteville, Arkansas, 72703, United States

  • Highlands Oncology Group

    Rogers, Arkansas, 72758, United States

  • Highlands Oncology Group

    Springdale, Arkansas, 72762, United States

  • Holy Cross Hospital

    Fort Lauderdale, Florida, 33308, United States

  • HonorHealth

    Scottsdale, Arizona, 85258, United States

  • Kanagawa cancer center

    Yokohama, Kanagawa, 2418515, Japan

  • Kharkiv Regional Specialized Dispensary of Radiation Protection of the Population

    Kharkiv, Kharkiv Oblast, 61166, Ukraine

  • LLC "Medicina Severnoy Stolitsy"

    Saint Petersburg, 191025, Russia

  • LLC "Severo-Zapadny Medical Center"

    Saint Petersburg, 192007, Russia

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • McGill University Health Centre

    Montreal, Quebec, H4A 3J1, Canada

  • Memorial Sloan Kettering Cancer Center

    Long Island City, New York, 11101, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Multiprofile Hospital of Active Treatment - Dobrich AD

    Dobrich, 9300, Bulgaria

  • Municipal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro City Council, "Dnipro State Me

    Dnipro, Dnipropetrovsk Oblast, 49102, Ukraine

  • National Cancer Center Hospital East

    Kashiwa, Chiba, 277-8577, Japan

  • Northwest Medical Specialties, PLLC

    Federal Way, Washington, 98003, United States

  • Northwest Medical Specialties, PLLC

    Gig Harbor, Washington, 98332, United States

  • Northwest Medical Specialties, PLLC

    Tacoma, Washington, 98405, United States

  • Private Medical Institution "Euromedservice"

    Pushkin, Sankt-Peterburg, 196603, Russia

  • Rainier Hematology-Oncology PC

    Puyallup, Washington, 98373, United States

  • Rainier Hematology-Oncology, PC

    Puyallup, Washington, 98373, United States

  • South Texas Accelerated Research Therapeutics, LLC

    San Antonio, Texas, 78229, United States

  • Specialized Hospital for Active Treatment of Oncology - Haskovo EOOD

    Haskovo, 6300, Bulgaria

  • Tennessee Oncology, PLLC

    Nashville, Tennessee, 37203, United States

  • The Oncology Institute of Hope and Innovation

    Glendale, California, 91204, United States

  • The Oncology Institute of Hope and Innovation

    Long Beach, California, 90805, United States

  • The Oncology Institute of Hope and Innovation

    Santa Ana, California, 92705, United States

  • The Oncology Institute of Hope and Innovation

    Whittier, California, 90602, United States

  • The Sarah Cannon Research Institute

    Nashville, Tennessee, 37203, United States

  • The Sarah Cannon Research Institute-Pharmacy

    Nashville, Tennessee, 37203, United States

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • UCHealth Lone Tree Medical Center

    Lone Tree, Colorado, 80124, United States

  • UCLA Hematology/Oncology - Parkside

    Santa Monica, California, 90404, United States

  • UCLA Hematology/Oncology - Santa Monica

    Santa Monica, California, 90404, United States

  • UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California, 94143, United States

  • UCSF Investigational Drugs Pharmacy

    San Francisco, California, 94158, United States

  • University Of Alabama at Birmingham

    Birmingham, Alabama, 35249, United States

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35233, United States

  • University of Colorado Hospital - Anschutz Cancer Pavilion (ACP)

    Aurora, Colorado, 80045, United States

  • University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)

    Aurora, Colorado, 80045, United States

  • University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)

    Aurora, Colorado, 80045, United States

  • University of Washington Medical Center

    Seattle, Washington, 98195, United States

  • Virginia G. Piper Cancer Center Pharmacy

    Scottsdale, Arizona, 85258, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.